Business
Result of Annual General Meeting
Result of Annual General Meeting.
About this update from Nuformix Plc
[{"type":"text","content":"\n\nNuformix plc\n(\"Nuformix\" or the \"Company\")\nResult of Annual General Meeting\nNuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting. \nThe results of the proxies appointing the Chair of the meeting are reported below:\n \n\n\n\n \n\n\nResolution\n\n\nOrdinary/ Special\n\n\nFor\n\n\n \n\n\nAgainst\n\n\n \n\n\nTotal votes cast\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo. of votes\n\n\n%\n\n\nNo. of votes\n\n\n%\n\n\n\n\n\n\n\n1\n\n\nTo re-appoint Daniel Gooding as a director\n \n\n\nOrdinary\n\n\n94,720,614\n\n\n99.67\n\n\n312,357\n\n\n0.33%\n\n\n95,032,971\n\n\n\n\n2\n\n\nTo re-appoint Julian Gilbert as a director\n \n\n\nOrdinary\n\n\n94,720,614\n\n\n99.67\n\n\n312,357\n\n\n0.33%\n\n\n95,032,971\n\n\n\n\n3\n\n\nTo re-appoint s Madeleine Kennedy as a director\n \n\n\nOrdinary\n\n\n92,448,034\n\n\n99.66\n\n\n312,357\n\n\n0.34%\n\n\n92,760,391\n\n\n\n\n4\n\n\nTo authorise the Directors to allot shares.\n \n\n\nOrdinary\n\n\n92,082,014\n\n\n96.19\n\n\n3,652,015\n\n\n3.81%\n\n\n95,734,029\n\n\n\n\n5\n\n\nTo authorise the Directors to disapply pre-emption rights.\n \n\n\nSpecial\n\n\n92,082,014\n\n\n98.52\n\n\n1,379,435\n\n\n1.48%\n\n\n93,461,449\n\n\n\n\n6\n\n\nTo authorise the Company to purchase its own shares.\n \n\n\nSpecial\n\n\n92,306,372\n\n\n96.32\n\n\n3,527,841\n\n\n3.68%\n\n\n95,834,213\n\n\n\n\n7\n\n\nTo authorise calling of a general meeting on 14 clear days' notice.\n \n\n\nSpecial\n\n\n93,093,402\n\n\n97.14\n\n\n2,740,811\n\n\n2.86%\n\n\n95,834,213\n\n\n\n \nA vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.\nThe Company's issued share capital is 744,309,368 ordinary shares of £0.001 each.\nEnquiries:\n \n\n\n\nNuformix plc\n\n\n \n\n\n\n\nDr Daniel Gooding, Executive Director\nDr Julian Gilbert, Non-executive Chairman\n \n\n\nVia IFC Advisory\n \n\n\n\n\nStanford Capital Partners Limited\n\n\n \n\n\n\n\nTom Price / Patrick Claridge (Corporate Finance)\n\n\n+44 (0) 20 3650 3650\n\n\n\n\...